The Pharmacovigilance Unit of Coimbra (UFC) is a Regional Unit of the National Pharmacovigilance System which is supported through a contract with the National Authority of Medicines and Health Products (INFARMED, IP).
The Data Centre is a structure to support Investigator Initiated Research providing Data Management and Electronic Data Capture Solutions.
The Quality Management System (QMS) has the necessary resources to provide the services and meet the needs and expectations of its Clients and interested parties.
The Translational Research and Technology Transfer Unit is responsible to provide all the support to facilitate and promote the transfer of R&D activities and pre-clinical studies to the development of clinical studies and to enhance the adoptions of best practices in the community.
Nesta edição do boletim “FARMACOVIGILÂNCIA: Atualizações de segurança de medicamentos” informa-se acerca de novas recomendações no tratamento da síndrome hepatorrenal com medicamentos que contêm terlipressi
Diabetes is a health condition that can affect many parts of the body, including the eyes. Routine eye exams can help identify the early stages of eye problems and protect a person’s vision.
Do not miss AIBILI's speakers at the roundtables on Personalised Medicine (Inês Pereira Marques) and Big Data/Artificial Intelligence (Luis Mendes). This Friday, September 16th during the Technology Exhibition dedica
AIBILI has been recognized as a Technology and Innovation Center. The Technology and Innovation Centers (CTI) are entities dedicated to the production, dissemination and transmission of knowledge, oriented to companies
The Honorary President of AIBILI, Prof. José Cunha-Vaz, was distinguished today, June 9th, in Berlin, Germany, with the Arnall Patz Medal. The Arnall Patz Medal is intended to distinguish outstanding contribu
AIBILI is happy to participate in the Azores Health Summit which will take place on 12-13/05/2022. Our President, Prof. Conceição Lobo, will share AIBILI’s experience in the development and implementation of diabetic
Do not miss the opportunity to hear about AIBILI Data Centre and its relevance for clinical research development. Carlos Domingues, AIBILI DataCentre Director will participate in this conference taking place on May 19
We are honoured to see our recent US Patent published representing another major milestone in AIBILI’s history. This patent US 11,2354,591 B2 follows the EU Patent EP3289565A1 that was received in August 2020. The t
AIBILI has participated through his Projects and Tech Transfer Manager, Daniel Sanches Fernandes, in the EATRIS PORTUGAL Hub Meeting on April 27, 2022 at INFARMED, I.P. in Lisbon.
AIBILI wishes you a joyous Holiday Season and a prosperous New Year!
Congratulations to our Investigators Cláudia Farinha and Patrícia Barreto that were awarded with the Prémio Plácido during the 64th C
Nesta edição do boletim “FARMACOVIGILÂNCIA: Atualizações de segurança de medicamentos” informa-se acerca de novas medidas para minimizar o risco de eventos adversos cardiovasculares major na utilização de Tof
Our honorary president, Prof. José Cunha-Vaz has spoken to the newspaper "Campeão das Provincias" in the scope of the #worldSightDay, celebrated today, October 14! In this communication, Prof. Cunha-Vaz raises the a
We are happy to announce that AIBILI is part of the PTCentroDiH - a regional hub to support small and medium-sized enterprises addressing the digital transformation challenge ahead. PTCentroDiH aims to act a
A AIBILI através do Dr. João Pedro Marques, grader e coordenador médico do CORC, contribui para o estudo inovador PIONEER, publicado na Nature (+ info
Nesta edição do boletim “FARMACOVIGILÂNCIA: Atualizações de segurança de medicamentos” informa-se acerca do risco aumentado de hemorragia pós-parto associada à utilização de medicamentos antidepressivos das
ONLINE COURSE Optical Coherence Tomography in the Posterior Segment - OCT and OCT-angiography April 17, 2021, 8:30 - 13h [GMT] Registration free but mandatory here: + info
Last March 18, the European Medicines Agency (EMA) announced the selected consortium to monitor possible adverse events to COVID-19 vaccines in Europe for the next 3 years. The consortium, led by the Netherl
We have receive our renewal of Data Centre (DC) certification by ECRIN – European Clinical Research Infrastructure Network! This is an important mark f
Nesta edição do boletim “FARMACOVIGILÂNCIA: Atualizações de segurança de medicamentos” informa-se acerca dos casos de hipertensão grave e síndrome de encefalopatia posterior reversível associada à utilizaç
AIBILI and Pathway Health Consulting are organizing a session focused on Funding and Prices of medicines in Portugal The session will opened by Prof. Francisco Batel-Marques and count with a presentation by
The JoinHealth - Autumn welcome webinar dedicated to Clinical research data will count with the participation of Rita Fernandes and Carlos Domingues from AIBILI - Association for Innovation and Biomedical Research on Lig
Nesta edição do boletim “FARMACOVIGILÂNCIA: Atualizações de segurança de medicamentos” informa-se acerca do risco de aneurisma e dissecção da artéria em doentes sob terapêutica com inibidores do VEGF, quand
Prof. Cunha-Vaz talks about ophthalmology, AIBILI and Coimbra. Please read complete interview here.
AIBILI is proud to announce that our researcher Prof. Rufino Silva was awarded with the 2020 European Society of Retina Specialists (EURETINA) Clinical Research Award with the project “Metabolomics: A Tool for Investig
Nesta edição do boletim “FARMACOVIGILÂNCIA: Atualizações de segurança de medicamentos” informa-se acerca das novas medidas para evitar erros na administração de medicamentos contendo leuprorrelina e relembra-
Don't miss the opportunity to participate in the Workshop dedicated to Good Clinical Practices, organized by CUF Academic and Research Medical Center and AIBILI-Association for Innovation and Biomedical Research on Light
The AIBILI General Assembly met on June 16, 2020, and approved new governing bodies composition as below: General Assembly: Coimbra University - Luís Simões da Silva SUCH –
Alerta de Segurança - Hidroxicloroquina: risco de reações adversas cardíacas em doentes com COVID-19 A hidroxicloroquina está a ser estudada no tratamento de doentes com COVID-19. Os resultados de estudos prelimina
Nesta edição do boletim “FARMACOVIGILÂNCIA: Atualizações de segurança de medicamentos” destaca-se a evidência acerca da utilização de hidroxicloroquina no tratamento de doentes com COVID-19 e potencial assoc
We would like to inform you that due to the containment measures for the Coronavirus outbreak the normal activity of AIBILI could be affected. However a contingence plan is already in place allowing our collaborators to
O Livro Branco das Doenças Raras é o resultado de um esforço conjunto do Grupo de Trabalho das Doenças Raras da P-BIO e do Centro de Avaliação de Tecnologias de Saúde e Investigação do Medicamento da AIBILI cont
A AIBILI e a ESEnfC assinaram um acordo de parceria para o desenvolvimento de atividades de investigação clínica destas duas instituições da cidade de Coimbra. Encontram, + info
Nesta edição do boletim “FARMACOVIGILÂNCIA: Atualizações de segurança de medicamentos” informa-se acerca de várias questões relacionadas com a segurança de domperidona, nivolumab, carfilzomib, mebutato de in
A CUF e a AIBILI estabeleceram uma parceria para o desenvolvimento de investigação clínica que irá permitir reforçar as competências de ambas as instituições e unir esforços para a concretização de projetos re
AIBILI aims to reinforce its Health Technology Assessment and Drug Research Centre with a Researcher on Economic Evaluation of Health Technologies Applications here: https
The journal Ophthalmic Research has just published a commemorative issue in Honour of Professor José Cunha-Vaz and his achievements in Diabetic Retinopathy, and ground-breaking contribution to basic sci
The 1st Meeting of the Drug Safety and Effectiveness Network (DruSER.net) took place on December 13, 2019. It was an important event to present this network coordinated by CHAD-AIBILI and t
The Centre for Health Technology Assessment and Drug Research of AIBILI will organize on December 13, 2019 the first meeting of the Drug Safety and Effectiveness Research Network. Please check here the p
AIBILI wishes you a joyous Holiday Season and a prosperous New Year!
AIBILI was present at the EATRIS - European Infrastructure for translational Medicine, National Hub Kick off Meeting, at INFARMED, Lisbon. In this meeting, which counted with the presence of EATRIS international repre
Nesta edição do boletim “FARMACOVIGILÂNCIA: Atualizações de segurança de medicamentos” informa-se acerca de várias questões relacionadas com a segurança de metotrexato, fingolimod, montelucaste, terapia horm
We are pleased to announce our latest publication on RetmarkerAMD® validation, published in the Eye newspaper, a Springer Nature group and official publication of the UK College of Ophthalmologists. By conducting a c
AIBILI was represented by Diogo Mendes at the 19th Annual Meeting of the ISoP International Society of Pharmacovigilance, in Bogotá (Colombia, October 26 to 29).
AIBILI organized in the EVICR.net annual Members Meeting, on October 24 and 25, at Infarmed (Lisbon) that was attended by about 100 participants who had the opportunity to update on the activities in the different subspe
Members of CHAD team were present on the 8th Pharmacovigilance Seminar of Spanish Pharmacovigilance System for Medicinal Products for Human Use, took place in Tordesillas, Spain, on October 23-25. This was the
Farmacovigilância: Atualizações de segurança de medicamentos – Vol. 6, Nº 2 - 2º Trimestre . Consulte: + info
AIBILI was present at TECH@PORTUGAL, on the 4th of July at Alfândega do Porto, an event that presented the best Portuguese innovation and technology. We would like to thank to our partner Retmarker to the support, an
Decorreu no dia 06/06/2019 o Demonstrador Tecnológico AIBILI. Este evento foi organizado em parceria pela Agência Nacional de Inovação (ANI) e a AIBILI, e contará com a presença do Sr. Prof. Eduardo Maldonado, Pres
[video width="1280" height="720" mp4="https://www.aibili.pt/wp-content/uploads/2019/06/Demonstradortecnologico.mp4"][/video] Partilhamos agora o testemunho do Prof. Cunha-Vaz sobre o nosso Demonstrador Tecnológico, r
AIBILI participated in the BIOMEET 2019 to celebrate 20 years of P-BIO. The event took place in Carcavelos on 07/05/2019. Please see here the programme<
Farmacovigilância: Atualizações de segurança de medicamentos – Vol. 6, Nº 1 Pharmacovigilance: Updates on drug safety is a quarterly publication issued by the Pharmacovigilance Unit of Coimbra (UFC) delivering to
A AIBILI recebeu a visita de estudantes de Eng.ª Física e Eng.ª Biomédica da Universidade e Coimbra no dia 19 de Março. Foi efetuada uma apresentação institucional da AIBILI pela Doutora Maria Madeira da UTT, uma
Pharmacovigilance: Updates on drug safety is a quarterly publication issued by the Pharmacovigilance Unit of Coimbra (UFC) delivering to patients and healthcare professionals information on the risks and safe use of medi
AIBILI has co-organized the Onco Pharmacovigilance Conference that was held in Coimbra on 24-25 of January 2019. ONCO Pharmacovigilance Conference is an event to join health professionals in order to address the safety a
Edifício Prof. Doutor José Cunha-Vaz
Azinhaga Sta. Comba, Celas
Portugal Geographical coordinates:
40º 13' 06,24" N
8º 24' 54,83" O
Telephone: +351 239 480100
Fax: +351 239 480117